Equity Profile

RPRX

Royalty Pharma plc

Health CarePharmaceuticals$24.2B

Aug5Wed

Pre-Earnings Brief

UpcomingQ4-2017Pre-Market9:00 AM EDT

Company Snapshot

Royalty Pharma plc is a healthcare company that focuses on acquiring and managing pharmaceutical royalties. With a market cap of $25 billion, it plays a significant role in the pharmaceutical industry by providing funding to biopharmaceutical companies, which can help accelerate drug development and commercialization.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how effectively the company is managing its royalty portfolio.

$1.18

Revenue

Revenue figures will provide insight into the company's royalty income and overall financial health.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Royalty Pharma reported a loss of $0.04 per share, which was below expectations. The revenue figures were not disclosed, but the company has faced challenges in meeting analyst estimates.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Royalty Pharma to report a positive EPS of $1.18 and revenue of $874 million, indicating a recovery in performance. However, given the company's recent history of missing estimates, there is a mix of optimism and caution among investors.

Bull Case

If Royalty Pharma meets or exceeds EPS and revenue expectations, it could signal a strong recovery and renewed investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet these expectations again, it may lead to further declines in stock price and investor sentiment, raising concerns about its operational effectiveness.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.18

EPS is a key indicator of profitability and will show how effectively the company is managing its royalty portfolio.

Revenue

$874M

Revenue figures will provide insight into the company's royalty income and overall financial health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.18?

This figure is crucial for assessing the company's profitability and could significantly influence investor sentiment.

What will be the revenue figure compared to the consensus of $874 million?

Revenue performance will provide insights into the effectiveness of the company's royalty management and overall growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Royalty Pharma to leverage its existing portfolio for better-than-expected earnings, given recent drug approvals.

Supporting Evidence

The company's royalty income could be more stable than anticipated due to ongoing demand for its key drugs.

Analysts may not fully account for the impact of new agreements that could enhance revenue streams.

Key Risk

If the company reports significant new royalty agreements, it could challenge the current consensus view.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will determine whether the company can recover from its recent earnings misses.

Bull Confirmed If

Achieving an EPS of $1.18 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $1.17 would support the bear case and raise concerns about the company's ability to generate profits.

Pre-Earnings Positioning

Options Market

Implied Move

±12.3%

The options market is pricing in a significant potential move in either direction, indicating uncertainty about the earnings report.

Detail

ATM IV

0.3%

30d HV

19.2%

Calls (25K)P/C Ratio: 0.01Puts (0)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Royalty Pharma beats expectations, history suggests a potential average one-day move of +2.89%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to a muted reaction, as investors weigh management's commentary against past performance.

Miss

A miss could result in a decline, with historical patterns indicating an average one-day drop of around -2.09%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or partnerships.
2Details on the performance of key drugs in the portfolio.
3Management's outlook on future revenue growth.
4Insights into operational efficiencies or cost management strategies.
5Comments on market conditions affecting the pharmaceutical industry.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how effectively the company is managing its royalty portfolio.

$1.18

Revenue

Revenue figures will provide insight into the company's royalty income and overall financial health.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Royalty Pharma meets or exceeds EPS and revenue expectations, it could signal a strong recovery and renewed investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet these expectations again, it may lead to further declines in stock price and investor sentiment, raising concerns about its operational effectiveness.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.18

EPS is a key indicator of profitability and will show how effectively the company is managing its royalty portfolio.

Revenue

$874M

Revenue figures will provide insight into the company's royalty income and overall financial health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.18?

This figure is crucial for assessing the company's profitability and could significantly influence investor sentiment.

What will be the revenue figure compared to the consensus of $874 million?

Revenue performance will provide insights into the effectiveness of the company's royalty management and overall growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Royalty Pharma to leverage its existing portfolio for better-than-expected earnings, given recent drug approvals.

Supporting Evidence

The company's royalty income could be more stable than anticipated due to ongoing demand for its key drugs.

Analysts may not fully account for the impact of new agreements that could enhance revenue streams.

Key Risk

If the company reports significant new royalty agreements, it could challenge the current consensus view.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will determine whether the company can recover from its recent earnings misses.

Bull Confirmed If

Achieving an EPS of $1.18 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $1.17 would support the bear case and raise concerns about the company's ability to generate profits.

Pre-Earnings Positioning

Options Market

Implied Move

±12.3%

The options market is pricing in a significant potential move in either direction, indicating uncertainty about the earnings report.

Detail

ATM IV

0.3%

30d HV

19.2%

Calls (25K)P/C Ratio: 0.01Puts (0)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Royalty Pharma beats expectations, history suggests a potential average one-day move of +2.89%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to a muted reaction, as investors weigh management's commentary against past performance.

Miss

A miss could result in a decline, with historical patterns indicating an average one-day drop of around -2.09%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or partnerships.
2Details on the performance of key drugs in the portfolio.
3Management's outlook on future revenue growth.
4Insights into operational efficiencies or cost management strategies.
5Comments on market conditions affecting the pharmaceutical industry.